Table 3 Response and survival by PD-L1 expression
Endpoint, na (%) | PD-L1 TC ≥ 25% | PD-L1 TC < 25% | PD-L1 TC ≥ 10% | PD-L1 TC < 10% | PD-L1 TC ≥ 50% | PD-L1 TC < 50% |
|---|---|---|---|---|---|---|
From diagnosis date to death | ||||||
 Median OS, months (range) | 8.2 (6.3–10.6) | 10.1 (8.3–12.2) | 9.6 (7.5–12.5) | 9.4 (7.9–11.4) | 7.9 (5.5–12.4) | 10.0 (8.5–11.8) |
 log-rank P value, PD-L1 high vs PD-L1 low/negative | 0.55 | 0.32 | 0.39 | |||
From first-line therapy | ||||||
 Number evaluable | 25 | 70 |  |  |  |  |
 ORRb, n (%) | ||||||
 Overall response rate | 10 (40.0) | 31 (44.3) |  |  |  |  |
 Complete response | 0 (0.0) | 1 (1.4) |  |  |  |  |
 Partial response | 10 (40.0) | 30 (42.9) |  |  |  |  |
 Duration of response, n | 8 | 24 |  |  |  |  |
 Median, weeks (range) | 10.6 (0.1–28.7) | 15.3 (1.7–52.3) |  |  |  |  |
 PFS, n | 73 | 169 | 110 | 132 | 41 | 201 |
Median, months (range) | 4.2 (2.6–4.8) | 4.8 (3.9–5.8) | 4.4 (3.3–4.9) | 4.9 (3.9–6.0) | 4.8 (3.2–6.1) | 4.5 (3.9–5.0) |
log-rank P value, PD-L1 high vs PD-L1 low/negative | 0.37 | 0.54 | 0.56 | |||
From second-line therapy | ||||||
 Number evaluable | 10 | 18 |  |  |  |  |
 ORRb, n (%) | ||||||
 Overall response rate | 2 (20.0) | 1 (5.6) |  |  |  |  |
 Complete response | 0 (0.0) | 0 (0.0) |  |  |  |  |
 Partial response | 2 (20.0) | 1 (5.6) |  |  |  |  |
 Duration of response, n | 2 | 1 |  |  |  |  |
 Median, weeks (range) | 10.6 (5.9–15.4) | 1.3 (1.3–1.3) |  |  |  |  |
 PFS, n | 25 | 58 | 38 | 45 | 13 | 70 |
 Median, months (range) | 4.1 (2.8–7.1) | 2.2 (1.6–4.0) | 4.1 (2.2–6.5) | 2.1 (1.6–3.6) | 6.3 (1.2–13.8) | 2.4 (1.6–3.8) |
 log-rank P value, PD-L1 high vs PD-L1 low/negative | 0.04 | 0.04 | 0.03 | |||